Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302

Molecular Cancer Therapeutics

Volumn 11, Issue 3, 2012, Pages 740-751

  Meng, Fanying ^a   Evans, James W ^a   Bhupathi, Deepthi ^a   Banica, Monica ^a   Lan, Leslie ^a   Lorente, Gustavo ^a   Duan, Jian Xin ^a   Cai, Xiaohong ^a   Mowday, Alexandra M ^b   Guise, Christopher P ^b   Maroz, Andrej ^b   Anderson, Robert F ^b   Patterson, Adam V ^b   Stachelek, Gregory C ^c   Glazer, Peter M ^c   Matteucci, Mark D ^a   Hart, Charles P ^a  

^a Threshold Pharmaceuticals   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOCHROME P450; FANCONI ANEMIA GROUP A PROTEIN; FLAVOPROTEIN; HISTONE H2AX; HISTONE H2AX GAMMA; OXIDOREDUCTASE; TH 302; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CYCLE ARREST; CONCENTRATION (PARAMETERS); CYTOTOXICITY; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; DRUG ACTIVATION; DRUG EXPOSURE; DRUG MECHANISM; EXCISION REPAIR; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; HYPOXIA; NONHUMAN; OXYGEN CONCENTRATION; PRIORITY JOURNAL; RADIOLYSIS; SENSITIVITY ANALYSIS; STOICHIOMETRY; TUMOR MICROENVIRONMENT;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; CHO CELLS; COMET ASSAY; CRICETINAE; CRICETULUS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; HCT116 CELLS; HISTONES; HT29 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; NEOPLASMS; NITROIMIDAZOLES; OXIDATION-REDUCTION; OXYGEN; PHOSPHORAMIDE MUSTARDS; PHOSPHORYLATION; PRODRUGS; SPHEROIDS, CELLULAR; TUMOR STEM CELL ASSAY;

EID: 84859378451     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0634     Document Type: Article

References (50)

1. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76. (Pubitemid 32219813)
2. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-39. (Pubitemid 47101660)
3. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393-410.
4. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47. (Pubitemid 38745529)
5. Teicher BA, Sartorelli AC. Nitrobenzyl halides and carbamates as prototype bioreductive alkylating agents. J Med Chem 1980;23:955-60. (Pubitemid 10091545)
6. Denny WA, Wilson WR. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J Med Chem 1986;29:879-87. (Pubitemid 16068792)
7. Firestone A, Mulcahy RT, Borch RF. Nitroheterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells. J Med Chem 1991;34:2933-5.
8. Chen Y, Hu L. Design of anticancer prodrugs for reductive activation. Med Res Rev 2009;29:29-64.
9. Reddy SB, Williamson SK. Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs 2009;18:77-87.
10. Denny WA, Wilson WR. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev 1993;12:135-51. (Pubitemid 23220677)
11. Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 2008;51:2412-20. (Pubitemid 351628502)
12. Guise CP, Wang AT, Theil A, Bridewell DJ, Wilson WR, Patterson AV. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol 2007;74:810-20. (Pubitemid 47212075)
13. Evans JW, Chernikova SB, Kachnic LA, Banath JP, Sordet O, Delahoussaye YM, et al. Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Res 2008;68:257-65. (Pubitemid 351380127)
14. Anderson RF, Denny WA, Li W, Packer JE, Tercel M, Wilson WR. Pulse radiolysis studies on the fragmentation of arylmethyl quaternary nitrogen mustards by one-electron reduction in aqueous solution. J Phys Chem A 1997;101:9704-9. (Pubitemid 127617212)
15. Wilson WR, Hicks KO, Pullen SM, Ferry DM, Helsby NA, Patterson AV. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat Res 2007;167:625-36. (Pubitemid 351292942)
16. Singleton DC, Li D, Bai SY, Syddall SP, Smaill JB, Shen Y, et al. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR). Cancer Gene Ther 2007;14:953-67. (Pubitemid 350115355)
17. Prosser GA, Copp JN, Syddall SP, Williams EM, Smaill JB, Wilson WR, et al. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. Biochem Pharmacol 2010;79:678-87.
18. Wardman P, Dennis MF, Everett SA, Patel KB, Stratford MR, Tracy M. Radicals from one-electron reduction of nitro compounds, aromatic Noxides and quinones: the kinetic basis for hypoxia-selective, bioreductive drugs. Biochem Soc Symp 1995;61:171-94.
19. Bolton JL, McClelland RA. Kinetics and mechanism of the decomposition in aqueous solutions of 2-(Hydroxyamino)imidazoles. J Am Chem Soc 1989;111:8172-81.
20. Tew DG. Inhibition of cytochrome P450 reductase by the diphenyliodonium cation. Kinetic analysis and covalent modifications. Biochemistry 1993;32:10209-15.
21. Durand RE, Olive PL. Evaluation of bioreductive drugs in multicell spheroids. Int J Radiat Oncol Biol Phys 1992;22:689-92.
22. Koch CJ. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 1993;53:3992-7. (Pubitemid 23267700)
23. Hicks KO, Siim BG, Pruijn FB, Wilson WR. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors. Radiat Res 2004;161:656-66. (Pubitemid 39149574)
24. GuiseCP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res 2010;70:1573-84.
25. Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, et al.DNAcross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity. Cancer Res 2009;69:3884-91.
26. Walton MI, Workman P. Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochem Pharmacol 1987;36:887-96. (Pubitemid 17038036)
27. Joseph P, Jaiswal AK, Stobbe CC, Chapman JD. The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles. Int J Radiat Oncol Biol Phys 1994;29:351-5. (Pubitemid 24166545)
28. Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL, Strafford IJ. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 1997;76:1338-47. (Pubitemid 27474977)
29. Guise CP, Abbattista MR, Tipparaju SR, Lambie NK, Su J, Li D, et al. Diflavin oxidoreductases activate the bioreductive prodrug PR104A under hypoxia. Mol Pharmacol 2012;81:1-10.
30. Olive PL, Banath JP. Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry B Clin Cytom 2009;76:79-90.
31. Clingen PH, Wu JY, Miller J, Mistry N, Chin F, Wynne P, et al. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol 2008;76:19-27.
32. Ostling O, Johanson KJ. Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. Biochem Biophys Res Commun 1984;123:291-8. (Pubitemid 14030137)
33. Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 2010;116:1524-7.
34. Jeggo PA, Kemp LM. X-ray-sensitive mutants of Chinese hamster ovary cell line. Isolation and cross-sensitivity to other DNA-damaging agents. Mutat Res 1983;112:313-27. (Pubitemid 14216061)
35. Hoy CA, Thompson LH, Mooney CL, Salazar EP. Defective DNA cross-link removal in Chinese hamster cell mutants hypersensitive to bifunctional alkylating agents. Cancer Res 1985;45:1737-43. (Pubitemid 15079132)
36. Fuller LF, Painter RB. A Chinese hamster ovary cell line hypersensitive to ionizing radiation and deficient in repair replication. Mutat Res 1988;193:109-21. (Pubitemid 18062212)
37. Kuraoka I, Kobertz WR, Ariza RR, Biggerstaff M, Essigmann JM, Wood RD. Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. J Biol Chem 2000;275:26632-6.
38. Liu N, Lamerdin JE, Tebbs RS, Schild D, Tucker JD, Shen MR, et al. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. Mol Cell 1998;1:783-93. (Pubitemid 128379063)
39. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003;22:5784-91. (Pubitemid 37176700)
40. Thompson LH, Hinz JM. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. Mutat Res 2009;668:54-72.
41. Gu Y, Patterson AV, Atwell GJ, Chernikova SB, Brown JM, Thompson LH, et al. Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther 2009;8:1714-23.
42. Bindra RS, Schaffer PJ, Meng A, Woo J, Maseide K, Roth ME, et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 2004;24:8504-18. (Pubitemid 39245072)
43. Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 2005;65:11597-604. (Pubitemid 41821719)
44. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008;68:605-14. (Pubitemid 351380090)
45. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010;28:3555-61.
46. Singh S, Le H, Shih SJ, Ho B, Vaughan AT. Suberoylanilide hydroxyamic acid modification of chromatin architecture affects DNA break formation and repair. Int J Radiat Oncol Biol Phys 2010;76:566-73.
47. Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, et al. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 2009;69:9367-75.
48. Choudhury A, Zhao H, Jalali F, Al Rashid S, Ran J, Supiot S, et al. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther 2009;8:203-13.
49. Wachters FM, van Putten JW, Maring JG, Zdzienicka MZ, Groen HJ, Kampinga HH. Selective targeting of homologous DNA recombination repair by gemcitabine. Int J Radiat Oncol Biol Phys 2003;57:553-62. (Pubitemid 37040953)
50. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 1997;147:541-50. (Pubitemid 27204090)